Hal Barron (GSK via YouTube)
January 19, 2022 02:43 AM ESTUpdated 11:12 AM
People

GSK R&D chief Hal Bar­ron jumps ship to run a $3B biotech start­up, Tony Wood tapped to re­place him

John Carroll

Editor & Founder

In a stun­ning switch, Glax­o­SmithK­line put out word ear­ly Wednes­day that R&D chief Hal Bar­ron is ex­it­ing the com­pa­ny af­ter 4 years — a rel­a­tive­ly brief …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times